Tim Greten

Tim Greten leads the gastrointestinal malignancies section at NCI and investigates the immunobiology of HCC, examining tumor immune evasion mechanisms and developing immunotherapy strategies including after locoregional therapies such as Y-90 radioembolization and TACE. His translational research has contributed to understanding how local ablative therapies modulate the HCC tumor immune microenvironment to potentially synergize with systemic immunotherapy. He leads first-in-human immunotherapy combination trials in HCC at the NCI Clinical Center. Greten's work spans immunotherapy development from preclinical models to early-phase clinical investigation in liver cancer.